ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of two abstracts relating to Cinryze™ (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.
Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents. Cinryze is not approved in the European Union or any of its member states.
"We are honored to be presenting HAE data at this important meeting," commented Peter Wijngaard, senior director, clinical development and European medical affairs, ViroPharma Europe. "ViroPharma is committed to raising awareness of HAE and educating healthcare professionals that may not have had any experience diagnosing and treating this rare disease."
The following abstracts from studies supported by Lev Pharmaceuticals, now ViroPharma Biologics, Inc., a fully-owned subsidiary of ViroPharma, were presented:
Poster Session 22: Phase 3 Results of Cinryze as Prophylactic and Acute Treatment of HAE